Fierce Biotech Fierce 15 2022

All the news on Fierce Biotech's Fierce 15 for 2022.

Former Fierce 15 honoree Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial for sarcoma patients.

Will Maddox Apr 16, 2026 10:12am

Sep 12, 2022 3:00am